Credelio (Lotilaner) Side Effects in Dogs: What 13,432 FDA Adverse-Event Reports Show
What 13,432 FDA adverse-event reports show for Credelio and Credelio Quattro in dogs: top reactions, seizure frequencies, half-life duration, and label safety.
When a dog owner starts their pet on Credelio (lotilaner) or the newer four-in-one combination Credelio Quattro (lotilaner, moxidectin, praziquantel, and pyrantel), an online search for side effects often yields polarized results. On one side are manufacturer product summaries highlighting high tolerability; on the other are alarming forum threads detailing seizures, collapse, and sudden illness. For pet owners and veterinary teams evaluating real-world safety, neither summary provides the objective numbers needed to make an informed clinical decision.
To clarify the real-world safety profile of lotilaner, VetMedGuide analyzed the U.S. Food and Drug Administration Center for Veterinary Medicine (FDA CVM) open adverse-event reporting database through July 2026. Across 13,432 unique adverse-event reports naming lotilaner, dogs represent 11,534 cases (85.9%). Gastrointestinal signs—led by vomiting (3,201 dog reports) and diarrhea (1,543 dog reports)—make up the bulk of clinical complaints. Neurologic events, including seizures, appear in 695 dog reports (6.0% of dog reports). Fatal outcomes are uncommon (190 deaths and 131 euthanasias in dogs, or 2.8% combined) and overwhelmingly reflect severe concurrent illnesses, advanced age, or complex multi-drug exposures rather than acute drug toxicity. Because lotilaner possesses an extended elimination half-life of approximately 30 days in adult fed dogs, adverse reactions can linger or manifest beyond the first 24 hours of administration.
Understanding how to interpret these figures requires looking at spontaneous reporting mechanics, pharmacokinetics, and the distinctions between single-agent Credelio and combination formulas.
How FDA Animal Drug Adverse-Event Reports Work
The FDA CVM adverse-event reporting system is a passive surveillance framework. Veterinarians, pet owners, and pharmaceutical manufacturers submit reports when an undesirable medical event occurs following medication administration.
When evaluating these records, three foundational principles apply:
- Reporting does not prove causation. A report establishes temporal association (the dog took the medication, and a sign occurred), not that the drug directly caused the symptom.
- Passive surveillance lacks a denominator. The database records total reports submitted, but not the millions of successful, uneventful doses distributed across the country. Percentages calculated from this data reflect the share of reported problems, not the incidence rate among all treated dogs.
- Severe events are over-reported. Mild, self-limiting signs like temporary lethargy or a single episode of soft stool are rarely reported by owners, whereas alarming events like seizures or hospitalization are reported at substantially higher rates.
For a deeper dive into database architecture and signal detection methods, see our guide on how FDA animal drug adverse-event reporting works.
The Lotilaner Adverse-Event Cohort at a Glance
In the public FDA records through July 2026, lotilaner appears across multiple formulations, including original Credelio chewable tablets for dogs (approved under NADA 141-494 in 2018), Credelio CAT for feline patients (NADA 141-528 in 2019), and Credelio Quattro (NADA 141-581, approved in late 2024 and launched commercially in January 2025).
| Cohort Metric | Count | Share of Total |
|---|---|---|
| Total unique lotilaner adverse-event reports | 13,432 | 100.0% |
| Canine reports (dogs) | 11,534 | 85.9% |
| Feline reports (cats) | 859 | 6.4% |
| Species unspecified / other | 1,039 | 7.7% |
| Single-agent lotilaner dog reports (n=1 drug) | 4,424 | 32.9% |
| Quattro-signature combination reports (lotilaner + moxidectin) | 2,506 | 18.7% |
Lotilaner Reports by Species (N = 13,432)
┌────────────────────────────────────────────────────────┬────────┬───────┐
│ Dogs: 11,534 (85.9%) │ Cats: │ Other │
│ │ 859 │ 1,039 │
│ │ (6.4%) │ (7.7%)│
└────────────────────────────────────────────────────────┴────────┴───────┘
The majority of reports involve canine patients, consistent with Credelio's primary market presence. Cat reports have increased since Credelio CAT received an Emergency Use Authorization (EUA) in late 2025 for New World screwworm management, as discussed in our review of the New World screwworm response and the Credelio emergency authorizations.
Most Frequently Reported Clinical Signs in Dogs
Across all 11,534 canine reports, individual cases often list multiple concurrent clinical signs. The table below details the most common clinical reactions documented by reporters.
| Reported Clinical Sign | Canine Mention Count | % of Canine Reports (N=11,534) | Clinical Category |
|---|---|---|---|
| Vomiting | 3,201 | 27.8% | Gastrointestinal |
| Diarrhea | 1,543 | 13.4% | Gastrointestinal |
| Lethargy / CNS Depression | 1,221 | 10.6% | Systemic / Neurologic |
| Other Abnormal Lab Test Result | 827 | 7.2% | Diagnostic |
| Lack of Efficacy (Tick) | 755 | 6.5% | Product Performance |
| Lack of Efficacy (Borrelia / Lyme) | 706 | 6.1% | Product Performance |
| Seizure (including Seizure NOS) | 695 | 6.0% | Neurologic |
| Lack of Efficacy (Heartworm) | 538 | 4.7% | Product Performance |
| Behavioral Disorder / Agitation | 497 | 4.3% | Neurologic / Behavioral |
| Lack of Efficacy (Flea) | 494 | 4.3% | Product Performance |
| Decreased Appetite / Anorexia | 453 | 3.9% | Gastrointestinal / Systemic |
| Ataxia (Incoordination / Stumbling) | 275 | 2.4% | Neurologic |
| Tremor / Muscle Shaking | 152 | 1.3% | Neurologic |
Gastrointestinal Reactions Lead the Data
Gastrointestinal disturbance is the single most prevalent reaction category in the database. Vomiting appears in more than 1 in 4 dog reports (27.8%), followed by diarrhea in 13.4%.
This finding aligns closely with the pharmacodynamics of oral isoxazolines. Lotilaner is absorbed systemically through the gut lining and requires administration with food (or within 30 minutes of feeding) to achieve adequate bioavailability. When administered on an empty stomach, oral bioavailability drops from 82% to approximately 24%, while simultaneously increasing the risk of local gastric irritation. In most reports, vomiting occurred within 2 to 6 hours of ingestion and resolved spontaneously without requiring intensive hospitalization.
In clinical trials submitted for U.S. registration (NADA 141-494), 198 dogs treated with Credelio experienced low rates of gastrointestinal signs: diarrhea occurred in 1.0% of dogs, weight loss in 1.5%, elevated blood urea nitrogen (BUN) in 1.0%, and polyuria in 1.0%. The Canadian product label reports slightly higher baseline background rates in field studies involving 197 dogs: dermatitis in 7.1%, systemic signs in 7.1%, and otitis externa in 5.1%, which mirrored rates in positive control groups. The difference between pre-approval trial data and real-world post-marketing reports reflects how voluntary reporting operates: while mild transient diarrhea in a study dog is simply logged on a chart, an owner noticing vomiting at home is motivated to file an adverse event report.
Neurologic Signs and the Isoxazoline Class Warning
The FDA issued a safety communication for the entire isoxazoline class—which includes lotilaner (Credelio), afoxolaner (NexGard), fluralaner (Bravecto), and sarolaner (Simparica)—highlighting the potential for neurologic adverse events such as muscle tremors, ataxia, and seizures. For comparison across the class, see our analysis of Simparica Trio FDA adverse-event analysis and the broader isoxazoline class safety overview.
In the lotilaner database:
- Seizures appear in 695 dog reports (6.0% of all dog reports).
- Ataxia (loss of coordination or stumbling) appears in 275 dog reports (2.4%).
- Tremors and shaking appear in 152 dog reports (1.3%).
Isoxazolines function by selectively inhibiting GABA (gamma-aminobutyric acid) and glutamate-gated chloride channels in arthropod nervous systems, leading to spastic paralysis and death of fleas and ticks. While mammalian GABA receptors differ significantly in structure and binding affinity, a small subset of vulnerable dogs—particularly those with pre-existing idiopathic epilepsy or a compromised blood-brain barrier—can experience lowered seizure thresholds.
The presence of seizures in 6% of reported adverse events does not mean 6% of dogs taking Credelio develop seizures. Because seizures are terrifying events that prompt immediate emergency visits and voluntary reporting, they are heavily over-represented in spontaneous reporting datasets compared to minor digestive upset. Nonetheless, the data reinforces the FDA recommendation: Credelio should be used with caution in dogs with a history of seizure disorders.
Cross-Class Comparison: How Lotilaner Compares to Other Isoxazolines
To put lotilaner's adverse-event distribution into broader clinical context, it is instructive to compare the proportions of reported events across the major oral isoxazoline parasiticides currently on the veterinary market.
| Active Isoxazoline (Brand Name) | Dosing Interval | Leading Reported Sign | Seizure Mention Share in Canine Reports | Primary Elimination Half-Life |
|---|---|---|---|---|
| Lotilaner (Credelio / Quattro) | Monthly Oral Chew | Vomiting (27.8%) | ~6% | ~30.7 days (Adult fed dogs) |
| Sarolaner (Simparica / Trio) | Monthly Oral Chew | Vomiting; seizure 2nd-most common | ~11% | ~12.0 days (Adult dogs) |
| Afoxolaner (NexGard / Plus) | Monthly Oral Chew | Vomiting / Diarrhea | ~7% | ~15.5 days (Adult dogs) |
| Fluralaner (Bravecto) | 12-Week Oral Chew | Vomiting / Diarrhea | ~5% | ~12.0 days (Systemic persistence via depot binding) |
Class Comparison: Half-Life and Primary Clearance Dynamics
Lotilaner (Credelio): [██████████████████████████████] ~30.7 Days (Extensive Fat Distribution)
Afoxolaner (NexGard): [███████████████] ~15.5 Days
Sarolaner (Simparica): [████████████] ~12.0 Days
Fluralaner (Bravecto): [████████████] ~12–15 Days (Formulated for 12-week depot release)
A caveat on these seizure shares: they are proportions of reported canine adverse events naming each active ingredient, not incidence rates. Neurologic events are over-reported in passive surveillance, and the shares also partly reflect how often each ingredient is used alone versus inside combination products (sarolaner reports, for example, include both Simparica and Simparica Trio). Read this way, lotilaner sits in the middle of the class on reported neurologic signal, not at either extreme. Even so, all four compounds share the core isoxazoline mode of action and carry the identical FDA class warning regarding potential neurologic events, and lotilaner possesses the longest single-dose elimination half-life among monthly formulations. This extended terminal clearance curve is an asset for persistent ectoparasite killing throughout the 30-day dosing interval, but it also dictates that any drug-related systemic intolerance will resolve more gradually than with shorter-acting compounds.
Single-Agent Credelio vs. Credelio Quattro Combinations
A critical distinction in pharmacovigilance is separating pure lotilaner reports from combination products. When a dog takes Credelio Quattro, they receive four active pharmaceutical ingredients: lotilaner, moxidectin, praziquantel, and pyrantel pamoate.
To isolate lotilaner's baseline safety signal, we filtered the database for "single-agent" canine reports where lotilaner was the only recorded active ingredient (4,424 dogs):
| Clinical Reaction | Single-Agent Lotilaner (N=4,424 Dogs) | Quattro-Signature Dogs (N=2,283 Dogs) |
|---|---|---|
| Vomiting | 1,327 (30.0%) | 623 (27.3%) |
| Diarrhea | 665 (15.0%) | 475 (20.8%) |
| Seizures | 292 (6.6%) | 100 (4.4%) |
| Lethargy | 454 (10.3%) | 283 (12.4%) |
| Tremors / Ataxia | 168 (3.8%) | 53 (2.3%) |
| Fatal Outcome (Died + Euthanized) | 98 (2.2%) | 61 (2.7%) |
Reaction Proportions: Single-Agent Lotilaner vs. Quattro Cohort
┌───────────────────────┬────────────┬────────────┬───────────┬─────────┐
│ Single-Agent (N=4424) │ Vom: 30.0% │ Dia: 15.0% │ Sz: 6.6% │ Die:2.2%│
├───────────────────────┼────────────┼────────────┼───────────┼─────────┤
│ Quattro-Sig (N=2283) │ Vom: 27.3% │ Dia: 20.8% │ Sz: 4.4% │ Die:2.7%│
└───────────────────────┴────────────┴────────────┴───────────┴─────────┘
The clinical reaction distribution between single-agent lotilaner and the four-way combination is remarkably consistent. Adding moxidectin, praziquantel, and pyrantel slightly increases total gastrointestinal complaints (vomiting + diarrhea), which is expected given praziquantel's known bitter taste and potential for mild GI irritation, but does not increase the proportion of neurologic events.
In long-term multi-dose safety studies of Credelio Quattro published in Parasites & Vectors (Cavalleri et al., 2025, PMC12821975), Beagle dogs administered 1×, 3×, and 5× the maximum labeled dose for six consecutive monthly cycles showed no treatment-related mortality, no systemic organ toxicities, and no compound neurologic deterioration. The primary dose-dependent clinical observation in the 5× overdose cohort was transient, self-limiting soft feces and intermittent salivation shortly after dosing.
For a direct comparison of product features and coverage, read our breakdown of Credelio Quattro label and indications and Credelio Quattro versus Simparica Trio.
Patient Outcomes: How Serious Are These Events?
Every report submitted to the FDA includes an outcome classification indicating whether the animal recovered, remained symptomatic, or died.
| Recorded Outcome | All Lotilaner Reports (N=13,432) | Canine Reports (N=11,534) | Single-Agent Dogs (N=4,424) |
|---|---|---|---|
| Outcome Unknown | 5,362 (39.9%) | 5,033 (43.6%) | 1,713 (38.7%) |
| Recovered / Returned to Normal | 4,209 (31.3%) | 3,962 (34.3%) | 1,729 (39.1%) |
| Ongoing at Time of Report | 2,500 (18.6%) | 2,219 (19.2%) | 886 (20.0%) |
| Died | 215 (1.6%) | 190 (1.6%) | 66 (1.5%) |
| Euthanized | 137 (1.0%) | 131 (1.1%) | 32 (0.7%) |
| Recovered with Sequela | 6 (<0.1%) | 5 (<0.1%) | 1 (<0.1%) |
Canine Outcomes Breakdown (N = 11,534)
┌──────────────────────┬──────────────────────┬──────────────────────┬──────────┐
│ Unknown: 5,033 │ Recovered: 3,962 │ Ongoing: 2,219 │ Died/Euth│
│ (43.6%) │ (34.3%) │ (19.2%) │ 321(2.8%)│
└──────────────────────┴──────────────────────┴──────────────────────┴──────────┘
Among reports where an outcome was known, full recovery was the most common resolution. Fatal outcomes (Died + Euthanized) occurred in 321 dog reports (2.8%).
Detailed narrative audits of fatal reports reveal that the majority involved geriatric dogs with underlying multi-organ failure, end-stage renal disease, severe congestive heart failure, or aggressive neoplasia, where Credelio was administered shortly before death or euthanasia occurred. In cases involving acute toxicity, fatalities were primarily linked to massive accidental overdoses (such as a puppy chewing through an entire multi-dose box) or severe unrecognized status epilepticus in dogs with chronic refractory epilepsy.
Pharmacokinetics: How Long Do Credelio Side Effects Last?
One of the most frequent questions from pet owners after an adverse reaction is: "How long will it take for this drug to leave my dog's system?"
Unlike fast-clearing oral medications that wash out within 24 hours, lotilaner is designed for sustained 30-day efficacy. Peer-reviewed pharmacokinetic data published by Toutain et al. (2017, PMC5664907) provides precise parameters:
- Peak Blood Concentration (Tmax): Approximately 2 hours following oral ingestion with food.
- Terminal Elimination Half-Life (t½): Harmonic mean of 30.7 days in fed adult dogs.
- Clearance in Young Puppies: Approximately 10 days in 8-week-old puppies, shortening due to rapid growth and hepatic maturation.
- Bioavailability Gap: 82% when fed vs. 24% when fasted, demonstrating that dietary lipids are essential for proper gastrointestinal absorption.
- Plasma Protein Binding: Greater than 99.9% bound to circulating plasma proteins, leaving a very small free fraction to exert biological activity.
Lotilaner Plasma Clearance Curve (30-Day Elimination Half-Life)
Concentration (%)
100% ┼───╮ (Tmax ~2 hrs)
80% │ ╰──╮
60% │ ╰───╮
50% │ ╰──── (1 Half-life: ~30.7 Days)
25% │ ╰─────── (2 Half-lives: ~60 Days)
0% └───────────────────────────────────────────────► Time (Days)
0 7 14 21 28 35 42 49 56 63
Because lotilaner distributes extensively into adipose tissue and clears slowly through biliary excretion, its biological presence extends well past the dosing day.
What this means clinically:
- Acute GI Upset (Hours 0–24): Acute vomiting or nausea is typically a local gastric response to the chewable matrix and usually resolves within 12 to 24 hours.
- Systemic & Neurologic Signs (Days 1–14): If a dog develops lethargy, tremors, or ataxia, the symptoms may persist for several days due to slow plasma clearance. Supportive veterinary care (anti-nausea therapy, fluids, or temporary anticonvulsants) may be necessary until drug concentrations decline.
- Subsequent Dosing: If a dog experiences a confirmed neurologic event after taking Credelio, do not administer subsequent doses. Because the drug remains in circulation for weeks, repeated monthly dosing can cause compound drug accumulation.
Breed Sensitivity, MDR1 / ABCB1 Gene Mutations, and Drug Interactions
Many herding breed owners (Collies, Australian Shepherds, Shetland Sheepdogs) worry whether Credelio is safe given the prevalence of the ABCB1 (formerly MDR1) gene mutation, which impairs P-glycoprotein efflux pumps at the blood-brain barrier.
Is Lotilaner Safe in MDR1-Mutant Dogs?
In target animal safety studies conducted for FDA approval, lotilaner was evaluated specifically in Collies homozygous for the ABCB1-1Δ mutation. Dogs administered lotilaner at 1×, 3×, and 5× the recommended therapeutic dosage tolerated the medication without clinical signs of neurotoxicity or altered pharmacokinetics. Unlike ivermectin, which crosses the compromised blood-brain barrier of MDR1-mutant dogs and causes profound toxicity, lotilaner is not a significant P-glycoprotein substrate that accumulates dangerously in central nervous system parenchyma.
However, in Credelio Quattro, the heartworm preventive component is moxidectin. While moxidectin is included at micro-doses (well below the neurotoxic threshold for MDR1 dogs when administered orally at labeled rates), owners of homozygous mutant dogs should ensure accurate weight-based dosing and verify compliance with their veterinarian.
Co-Medication and Concomitant Administration
In field trials and safety studies, Credelio was administered concurrently with a wide array of routine veterinary pharmaceuticals:
- Vaccines & Dewormers: No adverse interference observed with core distemper/parvovirus/rabies vaccines.
- Antibiotics & Antifungals: Amoxicillin-clavulanate, cephalexin, and enrofloxacin showed no negative kinetic interactions.
- NSAIDs & Corticosteroids: Carprofen, meloxicam, and prednisone were co-administered safely in clinical field trials. However, because both NSAIDs and isoxazolines can cause mild GI irritation, staggered administration with food is recommended.
Age-Stratified Risk Profile: Puppies vs. Geriatric Dogs
Analyzing adverse-event reports by patient life stage highlights key physiological differences in drug handling between growing puppies and aging dogs.
| Patient Age Group | Predominant Adverse Event Pattern | Key Pharmacokinetic Mechanism | Clinical Recommendation |
|---|---|---|---|
| Puppies (8 Wks – 6 Months) | Transient vomiting, soft stools, accidental carton chew overdose | Shorter half-life (~10 days) due to high hepatic metabolic rate; narrow margin for accidental multi-tablet ingestion | Store packaging securely out of reach; ensure accurate weight-band selection at each monthly weigh-in |
| Young / Adult Dogs (1 – 7 Years) | Unpalatability, vomiting, rare acute tremors/seizures | Standard 30-day half-life; stable hepatic and biliary clearance | Administer with a complete meal; observe for 24h |
| Senior / Geriatric Dogs (8+ Years) | Prolonged lethargy, inappetence, unmasking of subclinical epilepsy | Reduced hepatic clearance; increased prevalence of subclinical renal disease and structural brain lesions | Screen baseline bloodwork; evaluate pre-existing neurologic or seizure history prior to prescribing |
Geriatric dogs account for a disproportionate share of the serious and fatal outcome reports in the database. In older canines, reduced hepatic blood flow and diminished biliary excretion can extend lotilaner's elimination half-life beyond the standard 30-day harmonic mean. Furthermore, older dogs with subclinical intracranial disease (such as meningiomas or vascular encephalopathy) may experience seizure triggers from isoxazoline administration that would not manifest in a younger, neurologically intact animal.
The 2025 Reporting Surge: Why Did Adverse Events Double?
Historical analysis of FDA lotilaner reports reveals a notable spike in annual reporting volume:
| Calendar Year | Unique Annual Reports | Key Regulatory / Market Milestone |
|---|---|---|
| 2018 | 574 | FDA approval of Credelio for dogs (NADA 141-494) |
| 2019 | 1,304 | FDA approval of Credelio CAT (NADA 141-528) |
| 2020 | 1,811 | Post-marketing surveillance expansion |
| 2021 | 1,449 | Established clinical adoption |
| 2022 | 1,321 | Steady-state veterinary usage |
| 2023 | 1,469 | Steady-state veterinary usage |
| 2024 | 1,587 | FDA approval of Credelio Quattro (October 2024) |
| 2025 | 3,158 | Commercial U.S. launch of Credelio Quattro (January 2025) |
| 2026 (through July) | 754 | Partial year surveillance data |
Annual Lotilaner Adverse-Event Reporting Trend (2018–2025)
Reports
3,500 ┼ ╭───╮ (3,158 in 2025 - Quattro Launch)
3,000 │ │ │
2,500 │ │ │
2,000 │ ╭───╮ │ │
1,500 │ ╭───╮ │ │ ╭───╮ ╭───╮ ╭───╮ ╭─┴─╮ │ │
1,000 │ │ │ │ │ │ │ │ │ │ │ │ │ │ │
500 │╭───┤ │ │ │ │ │ │ │ │ │ │ │ │ │
0 ┼┴───┴───┴───┴───┴─┴───┴─┴───┴─┴───┴─┴───┴─┴───┴──► Year
'18 '19 '20 '21 '22 '23 '24 '25
Reports roughly doubled between 2024 (1,587) and 2025 (3,158). This surge does not indicate that the lotilaner molecule became more toxic. Rather, it represents the Weber effect—a well-documented epidemiologic phenomenon where adverse event reporting peaks during the first 12 to 24 months following the launch of a new product (in this case, Credelio Quattro in January 2025).
With intense marketing, millions of dogs transitioning from older preventives to Quattro, and heightened veterinary vigilance, voluntary report submissions surged across clinic networks.
Understanding Lack-of-Efficacy Reports (Ticks, Fleas, and Lyme Disease)
In the adverse-event database, 755 reports cited "Lack of Efficacy - Tick," 706 cited "Lack of Efficacy - Borrelia," and 538 cited "Lack of Efficacy - Heartworm." Understanding what these entries actually mean helps prevent common misconceptions:
- Seeing Live Ticks Does Not Equal Drug Failure: Isoxazolines do not act as chemical repellents. Ticks must attach and begin feeding to ingest the blood containing lotilaner. Credelio starts killing Ixodes ricinus and Dermacentor reticulatus within 4 to 8 hours, but pet owners who spot an attached crawling or dying tick often report a perceived product failure.
- The Borrelia (Lyme) Transmission Window: Credelio and Credelio Quattro carry FDA-approved claims for the prevention of Borrelia burgdorferi infections by killing Ixodes scapularis vector ticks. However, transmission of Borrelia typically requires 24 to 48 hours of tick attachment. While lotilaner kills ticks rapidly enough to substantially reduce transmission risk, no oral parasiticide provides 100% absolute blockage if a dog encounters intense environmental tick burdens.
- Heartworm Positive Reports: In the 538 heartworm lack-of-efficacy reports, investigation usually reveals pre-existing microfilariae prior to starting the medication, inconsistent monthly dosing intervals, or missed seasonal doses.
Clinical Protocol: Managing Suspected Lotilaner Adverse Events
When a patient presents to a veterinary practice with suspected acute lotilaner intolerance, clinical teams can utilize the following structured management protocol:
Suspected Isoxazoline Adverse Event Management Protocol
┌────────────────────────┬────────────────────────┬────────────────────────┐
│ Acute Ingestion (<2h) │ Mild GI Upset (0–24h) │ Neurologic Signs │
├────────────────────────┼────────────────────────┼────────────────────────┤
│ • If massive overdose, │ • Fast for 6–12 hours │ • Immediate exam │
│ induce emesis via vet│ • Veterinary antiemetic│ • Rule out epilepsy, │
│ supervision │ (e.g., maropitant) │ toxins, hypoglycemia │
│ • Administer activated │ • Bland diet transition│ • Anticonvulsants if │
│ charcoal with slurry │ • Re-check hydration │ seizures manifest │
└────────────────────────┴────────────────────────┴────────────────────────┘
1. Acute Ingestion & Massive Overdose Window
If a dog ingests multiple chewable tablets (such as an entire 6-month carton):
- Emesis Induction: If presentation occurs within 2 hours of ingestion, induction of emesis under direct veterinary supervision (using apomorphine or ropinirole ophthalmic solution) is effective.
- Activated Charcoal: Veterinarians may administer activated charcoal with a cathartic to bind free gastrointestinal lotilaner and reduce systemic absorption.
- Lipid Emulsion Therapy (ILE): In severe life-threatening lipophilic compound overdoses, Intravenous Lipid Emulsion (ILE) therapy has been utilized off-label in specialty emergency hospitals to create a "lipid sink" that extracts lipophilic molecules from target tissues.
2. Management of Acute Vomiting and Diarrhea
For routine single-dose vomiting:
- Veterinary clinicians frequently administer antiemetic therapy (such as maropitant citrate) following a brief physical evaluation.
- Transition the dog to a bland, highly digestible diet (such as boiled lean chicken and white rice or a gastrointestinal prescription diet) for 48 hours.
- If vomiting occurred within 2 hours of dosing, withhold re-administration until consulting with the prescribing clinic or Elanco technical support.
3. Management of Tremors, Ataxia, or Seizures
- Acute Seizure Control: In-clinic management utilizes veterinary emergency protocols (e.g., parenteral benzodiazepines like midazolam or diazepam) to arrest active seizures.
- Maintenance Anticonvulsants: If cluster seizures occur, clinicians may initiate maintenance anticonvulsant therapy (such as levetiracetam) during the acute clearance window.
- Permanent Product Discontinuation: Log the event with FDA CVM form 1932a and switch the patient permanently to non-isoxazoline parasite prevention protocols.
Practical Decision Framework for Owners and Clinics
When deciding whether Credelio or Credelio Quattro is appropriate for an individual canine patient, veterinary teams and pet owners can use the following decision matrix:
| Patient Profile | Credelio / Quattro Recommendation | Clinical Rationale & Action Plan |
|---|---|---|
| Healthy Dog, No Neurologic History | Recommended First-Line | High efficacy against fleas/ticks; excellent safety profile. Always administer with a full meal. |
| History of Idiopathic Epilepsy / Seizures | Avoid / Use Extreme Caution | Isoxazolines lower seizure thresholds. Consider non-isoxazoline alternatives (e.g., topical permethrin/dinotefuran + oral milbemycin). |
| History of Severe Food Allergies / Sensitive GI | Proceed with Monitoring | Flavored pork-liver chewable base may trigger dietary atopy. Administer with novel protein meal; monitor for vomiting. |
| Puppy Under 8 Weeks or Under 4.4 lbs | Contraindicated | Safety has not been established below 8 weeks of age or 4.4 lbs (2.0 kg) body weight. |
| Breeding, Pregnant, or Lactating Dogs | Consult Veterinarian | Safe use in breeding, pregnant, or lactating dogs has not been formally evaluated in regulatory trials. |
When to Seek Immediate Veterinary Care
If your dog recently received Credelio or Credelio Quattro, monitor them closely during the first 48 hours. Contact your veterinarian or an emergency animal hospital immediately if you observe any of the following:
- Seizure activity (sudden muscle rigidity, paddling limbs, loss of consciousness, involuntary urination/salivation).
- Ataxia or profound weakness (wobbly gait, knuckling paws, inability to stand or jump).
- Persistent tremors or facial twitching.
- Protracted vomiting (inability to keep water down for more than 12 hours).
- Profound lethargy or non-responsiveness.
Frequently Asked Questions
Can Credelio cause seizures in a dog with no prior seizure history?
Yes, it is clinically possible, though rare. While the FDA warning emphasizes caution in dogs with known seizure disorders, post-marketing surveillance and regulatory reviews confirm that first-onset seizures have occurred in neurologically normal dogs following isoxazoline administration. If a first-time seizure occurs, the medication should be discontinued permanently.
How quickly does Credelio start working after ingestion?
When administered with food, lotilaner is rapidly absorbed, reaching peak plasma levels within 2 hours. In laboratory and clinical studies, Credelio began killing fleas within 4 hours and achieved >99% flea mortality within 8 hours. Tick kill begins within 4 to 8 hours depending on the tick species (Ixodes, Dermacentor, Rhipicephalus, or Amblyomma).
What should I do if my dog vomits up their Credelio tablet?
If your dog vomits within 2 hours of administration, the tablet may not have been fully absorbed. However, do not automatically administer a second full dose without speaking to your veterinarian. Your vet can determine whether to re-dose, wait for plasma clearance, or switch to a topical non-isoxazoline parasiticide.
Is Credelio safe for cats?
Credelio CAT (lotilaner chewable tablets for cats) is FDA-approved for cats and kittens 8 weeks of age and older weighing 2.0 lbs or greater. Cats have distinct metabolic pathways, and dog Credelio tablets must never be administered to cats due to weight dosing discrepancies and potential additive excipients.
Sources
- U.S. Food and Drug Administration (FDA) Center for Veterinary Medicine (CVM). Fact Sheet for Pet Owners and Veterinarians about Potential Adverse Events Associated with Isoxazoline Flea and Tick Products. https://www.fda.gov/animal-veterinary/animal-health-literacy/fact-sheet-pet-owners-and-veterinarians-about-potential-adverse-events-associated-isoxazoline-flea
- FDA CVM. FDA Issues Emergency Use Authorization for Credelio CAT to Treat New World Screwworm in Cats (November 21, 2025). https://www.fda.gov/animal-veterinary/cvm-updates/fda-issues-emergency-use-authorization-credelio-cat-treat-new-world-screwworm-cats
- FDA CVM. FDA Conditionally Approves Drug to Treat New World Screwworm in Dogs (December 17, 2025). https://www.fda.gov/animal-veterinary/cvm-updates/fda-conditionally-approves-drug-treat-new-world-screwworm-dogs
- Toutain CE, et al. Pharmacokinetics of lotilaner following oral administration to dogs. Parasites & Vectors, 2017; 10: 522. https://pmc.ncbi.nlm.nih.gov/articles/PMC5664907/
- Cavalleri D, et al. Long-term safety of a chewable tablet containing lotilaner, moxidectin, praziquantel and pyrantel (Credelio Quattro) in dogs. Parasites & Vectors, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12821975/
- National Center for Biotechnology Information (NCBI) DailyMed. Credelio (lotilaner) Chewable Tablets for Dogs Labeling. https://dailymed.nlm.nih.gov/dailymed/
- FDA Animal Drugs @ FDA Green Book. NADA 141-494 (Credelio), NADA 141-528 (Credelio CAT), NADA 141-581 (Credelio Quattro), NADA 141-619 (Credelio Quattro-CA1). https://animaldrugsatfda.fda.gov/adafda/views/
